Business Description
Boston Scientific Corp
NAICS : 339112
SIC : 3841
ISIN : US1011371077
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.09 | |||||
Equity-to-Asset | 0.55 | |||||
Debt-to-Equity | 0.49 | |||||
Debt-to-EBITDA | 2.75 | |||||
Interest Coverage | 9.08 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 4.51 | |||||
Beneish M-Score | -2.46 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.6 | |||||
3-Year EBITDA Growth Rate | 33.4 | |||||
3-Year EPS without NRI Growth Rate | 28.8 | |||||
3-Year FCF Growth Rate | 18.7 | |||||
3-Year Book Growth Rate | 6.7 | |||||
Future 3-5Y EPS without NRI Growth Rate | 12.28 | |||||
Future 3-5Y Total Revenue Growth Rate | 9.05 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 64 | |||||
9-Day RSI | 54.86 | |||||
14-Day RSI | 55.36 | |||||
6-1 Month Momentum % | 22.21 | |||||
12-1 Month Momentum % | 26.91 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.32 | |||||
Quick Ratio | 0.82 | |||||
Cash Ratio | 0.18 | |||||
Days Inventory | 185.18 | |||||
Days Sales Outstanding | 53.87 | |||||
Days Payable | 75.38 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.1 | |||||
Shareholder Yield % | -0.1 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 69.4 | |||||
Operating Margin % | 16.96 | |||||
Net Margin % | 11.19 | |||||
FCF Margin % | 11.8 | |||||
ROE % | 8.67 | |||||
ROA % | 4.74 | |||||
ROIC % | 6.53 | |||||
ROC (Joel Greenblatt) % | 51.47 | |||||
ROCE % | 7.7 | |||||
Years of Profitability over Past 10-Year | 7 |
GF Value Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 63.01 | |||||
Forward PE Ratio | 29.5 | |||||
PE Ratio without NRI | 32.89 | |||||
Shiller PE Ratio | 83.76 | |||||
Price-to-Owner-Earnings | 65.9 | |||||
PEG Ratio | 4.44 | |||||
PS Ratio | 6.93 | |||||
PB Ratio | 5.13 | |||||
Price-to-Free-Cash-Flow | 58.17 | |||||
Price-to-Operating-Cash-Flow | 39.57 | |||||
EV-to-EBIT | 48.07 | |||||
EV-to-Forward-EBIT | 28.99 | |||||
EV-to-EBITDA | 31.38 | |||||
EV-to-Forward-EBITDA | 21.72 | |||||
EV-to-Revenue | 7.6 | |||||
EV-to-Forward-Revenue | 6.93 | |||||
EV-to-FCF | 63.26 | |||||
Price-to-Projected-FCF | 3.51 | |||||
Price-to-DCF (Earnings Based) | 2.08 | |||||
Price-to-DCF (FCF Based) | 1.97 | |||||
Price-to-Median-PS-Value | 1.44 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.76 | |||||
Earnings Yield (Greenblatt) % | 2.08 | |||||
FCF Yield % | 1.71 | |||||
Forward Rate of Return (Yacktman) % | 13.14 |